

Laurent Remontet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8805301/publications.pdf>

Version: 2024-02-01

65
papers

2,886
citations

218677

26
h-index

175258

52
g-index

70
all docs

70
docs citations

70
times ranked

3681
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. <i>Lancet Oncology</i> , The, 2019, 20, 100-109.	10.7	701
2	Cancer incidence and mortality in France over the period 1980â€“2005. <i>Revue D'Epidemiologie Et De Sante Publique</i> , 2008, 56, 159-175.	0.5	418
3	Cancer incidence and mortality in France over the 1980â€“2012 period: Solid tumors. <i>Revue D'Epidemiologie Et De Sante Publique</i> , 2014, 62, 95-108.	0.5	184
4	Effect of Age, Gender, and Diabetes on Excess Death in End-Stage Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2125-2134.	6.1	146
5	Incidence of gastrointestinal cancers in France. <i>Gastroenterologie Clinique Et Biologique</i> , 2004, 28, 877-881.	0.9	102
6	Estimating net survival: the importance of allowing for informative censoring. <i>Statistics in Medicine</i> , 2012, 31, 775-786.	1.6	74
7	Breast cancer incidence using administrative data: correction with sensitivity and specificity. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 660-666.	5.0	67
8	Cancer net survival on registry data: Use of the new unbiased Poharâ€™Perme estimator and magnitude of the bias with the classical methods. <i>International Journal of Cancer</i> , 2013, 132, 2359-2369.	5.1	62
9	Focus on an unusual rise in pancreatic cancer incidence in France. <i>International Journal of Epidemiology</i> , 2017, 46, 1764-1772.	1.9	49
10	Thyroid cancer: is the incidence rise abating?. <i>European Journal of Endocrinology</i> , 2009, 160, 71-79.	3.7	47
11	Survival of solid cancer patients in France, 1989â€“2013: a population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, 461-468.	1.3	47
12	Prognostic factors and long-term results of pulmonary metastasectomy for pediatric histologiesâ††. <i>European Journal of Cardio-thoracic Surgery</i> , 2008, 34, 1240-1246.	1.4	39
13	Conditional relative survival of cancer patients and conditional probability of death. <i>Cancer</i> , 2009, 115, 4616-4624.	4.1	37
14	A multilevel excess hazard model to estimate net survival on hierarchical data allowing for non-linear and non-proportional effects of covariates. <i>Statistics in Medicine</i> , 2016, 35, 3066-3084.	1.6	37
15	Socioeconomic environment and disparities in cancer survival for 19 solid tumor sites: An analysis of the French Network of Cancer Registries (FRANCIM) data. <i>International Journal of Cancer</i> , 2019, 144, 1262-1274.	5.1	35
16	Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study. <i>Blood</i> , 2011, 118, 4331-4337.	1.4	33
17	Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5). <i>Lancet Haematology</i> , the, 2015, 2, e481-e491.	4.6	33
18	Cancer incidence in France over the 1980â€“2012 period: Hematological malignancies. <i>Revue D'Epidemiologie Et De Sante Publique</i> , 2016, 64, 103-112.	0.5	33

#	ARTICLE	IF	CITATIONS
19	Unbiased estimates of long-term net survival of solid cancers in France. <i>International Journal of Cancer</i> , 2013, 132, 2370-2377.	5.1	31
20	Probabilities of dying from cancer and other causes in French cancer patients based on an unbiased estimator of net survival: A study of five common cancers. <i>Cancer Epidemiology</i> , 2013, 37, 857-863.	1.9	30
21	Sensitivity and specificity of different methods for cystic fibrosis-related diabetes screening: is the oral glucose tolerance test still the standard?. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2017, 30, 27-35.	0.9	30
22	A dietary supplement to improve the quality of sleep: a randomized placebo controlled trial. <i>BMC Complementary and Alternative Medicine</i> , 2010, 10, 29.	3.7	29
23	Changes in the risk of death from cancer up to five years after diagnosis in elderly patients: A study of five common cancers. <i>International Journal of Cancer</i> , 2010, 127, 924-931.	5.1	28
24	Flexible modeling of competing risks in survival analysis. <i>Statistics in Medicine</i> , 2010, 29, 2453-2468.	1.6	28
25	Trends in the incidence of digestive cancers in France between 1980 and 2005 and projections for the year 2010. <i>European Journal of Cancer Prevention</i> , 2011, 20, 375-380.	1.3	28
26	Early parenteral lipids and growth velocity in extremely-low-birth-weight infants. <i>Clinical Nutrition</i> , 2014, 33, 502-508.	5.0	28
27	Estimating infra-national and national thyroid cancer incidence in France from cancer registries data and national hospital discharge database. <i>European Journal of Epidemiology</i> , 2007, 22, 607-614.	5.7	27
28	Trends in incidence of digestive cancers in France. <i>European Journal of Cancer Prevention</i> , 2008, 17, 13-17.	1.3	26
29	A new approach to estimate time-to-cure from cancer registries data. <i>Cancer Epidemiology</i> , 2018, 53, 72-80.	1.9	25
30	Flexible and structured survival model for a simultaneous estimation of non-linear and non-proportional effects and complex interactions between continuous variables: Performance of this multidimensional penalized spline approach in net survival trend analysis. <i>Statistical Methods in Medical Research</i> , 2019, 28, 2368-2384.	1.5	24
31	On a general structure for hazard-based regression models: An application to population-based cancer research. <i>Statistical Methods in Medical Research</i> , 2019, 28, 2404-2417.	1.5	24
32	Multi-Dimensional Penalized Hazard Model with Continuous Covariates: Applications for Studying Trends and Social Inequalities in Cancer Survival. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2019, 68, 1233-1257.	1.0	23
33	Describing the association between socioeconomic inequalities and cancer survival: methodological guidelines and illustration with population-based data. <i>Clinical Epidemiology</i> , 2018, Volume 10, 561-573.	3.0	21
34	A Suitable Approach to Estimate Cancer Incidence in Area without Cancer Registry. <i>Journal of Cancer Epidemiology</i> , 2011, 2011, 1-11.	1.1	20
35	survPen: an R package for hazard and excess hazard modelling with multidimensional penalized splines. <i>Journal of Open Source Software</i> , 2019, 4, 1434.	4.6	19
36	National cancer incidence is estimated using the incidence/mortality ratio in countries with local incidence data: Is this estimation correct?. <i>Cancer Epidemiology</i> , 2013, 37, 270-277.	1.9	17

#	ARTICLE	IF	CITATIONS
37	Cancer incidence estimation at a district level without a national registry: A validation study for 24 cancer sites using French health insurance and registry data. <i>Cancer Epidemiology</i> , 2013, 37, 99-114.	1.9	16
38	Time-to-cure and cure proportion in solid cancers in France. A population based study. <i>Cancer Epidemiology</i> , 2019, 60, 93-101.	1.9	16
39	Is Pneumonectomy After Induction Chemotherapy for Non-small Cell Lung Cancer a Reasonable Procedure? A Multicenter Retrospective Study of 228 Cases. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1496-1503.	1.1	15
40	A joint frailty model to estimate the recurrence process and the disease-specific mortality process without needing the cause of death. <i>Statistics in Medicine</i> , 2014, 33, 3147-3166.	1.6	13
41	Incidence of major smoking-related cancers: Trends among adults aged 20-44 in France from 1982 to 2012. <i>Cancer Epidemiology</i> , 2015, 39, 707-713.	1.9	13
42	Low phosphatemia in extremely low birth weight neonates: A risk factor for hyperglycemia?. <i>Clinical Nutrition</i> , 2016, 35, 1059-1065.	5.0	13
43	Competing risk models to estimate the excess mortality and the first recurrent-event hazards. <i>BMC Medical Research Methodology</i> , 2011, 11, 78.	3.1	12
44	Hazard regression model and cure rate model in colon cancer relative survival trends: are they telling the same story?. <i>European Journal of Epidemiology</i> , 2008, 23, 251-259.	5.7	11
45	Trends in excess mortality in follicular lymphoma at a population level. <i>European Journal of Haematology</i> , 2015, 94, 120-129.	2.2	11
46	Multidimensional penalized splines for incidence and mortality-trend analyses and validation of national cancer-incidence estimates. <i>International Journal of Epidemiology</i> , 2020, 49, 1294-1306.	1.9	11
47	Joint use of epidemiological and hospital medico-administrative data to estimate prevalence. Application to French data on breast cancer. <i>Cancer Epidemiology</i> , 2012, 36, 116-121.	1.9	10
48	Effects of Age and Disease Duration on Excess Mortality in Patients With Multiple Sclerosis From a French Nationwide Cohort. <i>Neurology</i> , 2021, 97, e403-e413.	1.1	10
49	Oral noregestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1458-1463.	3.0	8
50	Socioeconomic Environment and Survival in Patients with Digestive Cancers: A French Population-Based Study. <i>Cancers</i> , 2021, 13, 5156.	3.7	8
51	New insights into survival trend analyses in cancer population-based studies: the SUDCAN methodology. <i>European Journal of Cancer Prevention</i> , 2017, 26, S9-S15.	1.3	7
52	Relationship between adverse drug reactions and unlicensed/off-label drug use in hospitalized children (EREMI): A study protocol. <i>Therapie</i> , 2021, 76, 675-685.	1.0	7
53	For a sound use of health care data in epidemiology: evaluation of a calibration model for count data with application to prediction of cancer incidence in areas without cancer registry. <i>Biostatistics</i> , 2019, 20, 452-467.	1.5	6
54	Incidence and survival of gastric non-Hodgkin's lymphoma: A population-based study from the Association of the French Cancer Registries (FRANCIM). <i>Acta Oncologica</i> , 2009, 48, 977-983.	1.8	5

#	ARTICLE	IF	CITATIONS
55	Reliability of recording uterine cancer in death certification in France and age-specific proportions of deaths from cervix and corpus uteri. <i>Cancer Epidemiology</i> , 2011, 35, 243-249.	1.9	5
56	Performance of two formal tests based on martingales residuals to check the proportional hazard assumption and the functional form of the prognostic factors in flexible parametric excess hazard models. <i>Biostatistics</i> , 2017, 18, 505-520.	1.5	5
57	Preoperative Topical Estrogen Treatment vs Placebo in 244 Children With Midshaft and Posterior Hypospadias. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2422-2429.	3.6	5
58	Description of an approach based on maximum likelihood to adjust an excess hazard model with a random effect. <i>Cancer Epidemiology</i> , 2013, 37, 449-456.	1.9	4
59	Farnesoid X Receptor Targeting for Hepatitis C: Study Protocol for a Proof-of-concept Trial. <i>Therapie</i> , 2012, 67, 423-427.	1.0	3
60	Framework and optimisation procedure for flexible parametric survival models. <i>Statistics in Medicine</i> , 2015, 34, 3376-3377.	1.6	3
61	Artefact-free trends in breast cancer incidence over two decades in a whole French Département. <i>Breast</i> , 2008, 17, 580-586.	2.2	2
62	How to produce sound predictions of incidence at a district level using either health care or mortality data in the absence of a national registry: the example of cancer in France. <i>International Journal of Epidemiology</i> , 2021, 50, 279-292.	1.9	1
63	Author's reply to: Estimating net survival in population-based cancer studies. <i>International Journal of Cancer</i> , 2013, 133, 522-523.	5.1	0
64	Trends in probabilities of death owing to cancer and owing to other causes in patients with colon cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 570-576.	1.6	0
65	Modeling excess hazard with time-to-cure as a parameter. <i>Biometrics</i> , 2021, 77, 1289-1302.	1.4	0